Bayer’s LYNKUET (elinzanetant) receives expanded authorization in Canada for breast cancer-related vasomotor symptoms Bayer Canada announced that Health Canada has expanded the market authorizat...
Takeaways: Itovebi’s addition to Québec’s RAMQ list means eligible patients with advanced HR‑positive, HER2‑negative, PIK3CA‑mutated breast cancer can now access a targeted pill that, in the INAVO120 ...
Takeaways: Gazyva’s reimbursement recommendation is a clear commercial win for Roche because it opens the door to public coverage in a high-need, specialty autoimmune market...
